# A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors

> **NCT05425602** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Maxinovel Pty., Ltd.** · enrollment: 108 (estimated)

## Conditions studied

- Advanced / Metastatic Solid Tumors

## Interventions

- **DRUG:** MAX-40279-01: 50mg/70mg

## Key facts

- **NCT ID:** NCT05425602
- **Lead sponsor:** Maxinovel Pty., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-31
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2022-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05425602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05425602, "A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05425602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*